Dror Ortho-Design, Inc. filed a Form 10-Q with the SEC on November 16, 2026, reporting unaudited financial results for the quarterly period ended September 30, 2026, and disclosing a nine-month net loss of $1,784,697.
Key Highlights
- Nine-month net loss: The company reported a net loss of $1,784,697 for the nine months ended September 30, 2026, compared with a net loss of $1,988,989 for the same period in 2025.
- Third-quarter net loss: Net loss for the three months ended September 30, 2026 was $520,888, versus $653,528 in the prior-year quarter.
- Cash position: Cash at September 30, 2026 stood at $25,046, down from $228,540 at December 31, 2025.
- Total stockholders' deficit: The accumulated deficit reached $23,836,240 at September 30, 2026, resulting in a total stockholders' deficit of $4,458,408.
- Convertible notes and derivative liability: Convertible promissory notes, net, totaled $2,249,164, with an associated derivative liability of $992,991, as of September 30, 2026.
- Shares outstanding: Common shares issued and outstanding were 976,997,116 as of November 16, 2026, following the issuance of 20,000,000 shares in respect of future services in the first quarter of 2026.
- Operating cash use: Net cash used in operating activities for the nine months ended September 30, 2026 was $1,071,002, funded primarily by $870,000 in proceeds from convertible promissory notes.
Dror Ortho-Design Financial Condition and Results for the Nine Months Ended September 30, 2026
According to the filing, Dror Ortho-Design, Inc. - which lists no securities on any national exchange, with the cover page showing "None" for trading symbol and exchange - recorded total operating expenses of $1,433,146 for the nine months ended September 30, 2026, consisting of $388,440 in research and development costs and $1,044,706 in general and administrative expenses. This compares with total operating expenses of $1,777,845 in the same period of 2025, which included $39,170 in share-based compensation that did not recur in 2026.
The company disclosed that total other expense, net, for the nine months ended September 30, 2026 was $351,551, driven by $442,224 in convertible promissory note discount amortization, partially offset by a $100,490 favorable change in the fair value of the derivative liability. The balance sheet showed total liabilities of $4,736,615 against total assets of $278,207 at September 30, 2026, reflecting a continuing stockholders' deficit. Total current liabilities included a Registration Rights Agreement liability of $520,000 that was unchanged from December 31, 2025.
The filing disclosed that in the first quarter of 2026, the company issued 20,000,000 shares of common stock valued at $200,000 in respect of future services, raising common shares outstanding from 956,997,116 to 976,997,116. Cash at the end of the nine-month period was $25,046, down from $228,540 at the beginning of the period, with financing activities providing $870,000 through proceeds from convertible promissory notes. The company reported no provision for income taxes for either the three- or nine-month periods in 2026 or 2025.
What Was Disclosed
Dror Ortho-Design, Inc. filed its 10-Q for the quarter ended September 30, 2026, disclosing a nine-month net loss of $1,784,697, a cash balance of $25,046, a total stockholders' deficit of $4,458,408, and an accumulated deficit of $23,836,240, with operations funded primarily through convertible promissory notes.





Please wait processing your request...